Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. - Test2 - elhamkhani - TriplyDB

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

http://www.wikidata.org/entity/Q39910350

about

Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin GPC-3 in hepatocellular carcinoma: current perspectives Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies Glypican-3: a new target for cancer immunotherapy.Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.3β-hydroxysterol δ24-reductase on the surface of hepatitis C virus-related hepatocellular carcinoma cells can be a target for molecular targeting therapy.Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation.Aptamers against Cells Overexpressing Glypican 3 from Expanded Genetic Systems Combined with Cell Engineering and Laboratory Evolution High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma.Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy.Glypican-3 antibodies: a new therapeutic target for liver cancer.Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2.Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma.GPI transamidase and GPI anchored proteins: oncogenes and biomarkers for cancer.Systemic therapies in hepatocellular carcinoma: present and future.Novel therapeutic targets and predictive markers for hepatocellular carcinoma.Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.Shed proteoglycans in tumor stroma.Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma.T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC.A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.TriFabs--Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery.Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2.Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins Glypican-3 expression in clear cell adenocarcinoma of the ovary.

P2860

Q26738860-88C0EEC1-9069-44E0-A401-30930C712F60 Q26772321-8AB5CEB8-9070-4DBB-AC7C-607B36702B56 Q26827487-7E3F074A-3243-44CD-8C17-C6B60B01B2B7 Q27015134-4A337783-7144-4B33-B8A7-4AE43324517F Q28066774-2A762F06-D686-47F7-93A3-FDB4844AB71B Q28068437-5B1E32CD-7A17-48D7-ACAA-B88C0F9BF1DB Q33850265-8B397E7D-C8D9-402C-B4DD-5C9EE8FB8E8F Q33895113-6DF37D81-0AF1-4441-896E-D5A09665CA6B Q34543102-9CE1CE1D-C356-4D06-A665-FC5650997137 Q34675546-91E06A8D-1B70-4630-BCE7-B178F5A93A69 Q35051445-E4203BE2-89CF-4095-8A3E-6A2881F55472 Q35170403-EC22FDCC-9DA3-45F6-B81E-DF689CA6782E Q35602416-BF2DA5FD-1303-4693-8A16-092BB83B653F Q35963772-2327ACC1-A7A6-49F9-A7C0-E580E419CDE3 Q36124808-02A59C98-8D2F-4708-8921-0D40FD7D1DEA Q36402695-BC7B0CDC-BC56-4AC4-BF0C-D51B00B5CCE4 Q36598885-1AC03680-A732-4991-BFB7-CD9B14B61944 Q36712597-2A986866-451E-475F-9898-5051C89E6454 Q37031710-818220BA-8944-47B4-9956-3333E80C2E7F Q37491353-3663F644-FAE3-444D-9BC5-A1CF204C5FA9 Q37625736-0323CBE9-D4F8-44C4-9BD1-99BB96230564 Q37685728-962A52D5-EB72-4D8C-B1CF-FF2E1F94BB29 Q37873514-316C609B-3F18-414A-AC10-991C80969F56 Q38131553-69E11AA7-F634-4F92-9462-8FAAE8D638C6 Q38150875-4F087112-EB37-403F-9C93-B390F465FBCD Q38440838-0A2FD0E5-5454-4EAD-B483-386B96D987BF Q38740040-0B427498-7DC7-4CF5-8AEF-3FA5CB18135F Q38873430-D900DEEE-EF53-4777-A219-E6804CD608BE Q38882752-EA0E96CA-30C3-412F-BD01-4C57A8712FAC Q39000945-92CBB883-F21C-4583-BAF9-6D51DB10B350 Q39358916-4BF9C1DB-FC8E-4D06-AA1A-E3CDD0B63396 Q39378285-CE77B082-0E92-4B9C-AC59-A209989A2551 Q39644772-C4C2B7D5-E4B7-4778-A735-4D2AC2E7D9D3 Q39676817-FFFDD182-FF0A-4D25-A5D8-033BC5C40BE3 Q40064011-57A4ADFE-9434-495A-BCB9-C638469E05E4 Q40069479-9088858F-BE20-4DD5-9251-34388FA76344 Q41924939-4107CE52-937C-42A9-AE6D-261425B61F7A Q42134157-9C1F1442-3B15-4699-876E-986EE69F4554 Q42856089-7379C662-CEB2-4F8D-88CC-A7870A1BD698 Q44268931-46BBA677-51B0-4FF6-8722-06A8769FFFCE

P2860

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

http://www.wikidata.org/entity/Q39910350

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

@en

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

@nl

type

label

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

@en

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

@nl

prefLabel

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

@en

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

@nl

P1433

Q39910350-83A89C13-6599-4BA5-BC05-44752F20A767

P1476

Q39910350-91046576-44A3-415F-AC0C-E9D62C396BB3

P2093

Q39910350-0BEC4421-785B-46BE-A85F-CD0C82AFC447

Q39910350-0C07E82E-C593-4839-9B81-5CEA5E8D5E9E

Q39910350-150D2A35-10BD-4671-87B6-E9FCD04EE8FB

Q39910350-19A32F5E-80FA-40AF-8F28-81405FD6BF04

Q39910350-234E5BE0-D43E-4FF4-A140-5056189FEEE0

Q39910350-3D811F4E-5B23-4B33-ADBC-6C735EAE4966

Q39910350-4060BC98-9FCC-4F1F-9085-10E11CA39A29

Q39910350-5DA6529D-727C-4834-A4F4-4CF2C747B31A

Q39910350-6D6BB552-0454-471D-99BF-5EAC42CF0257

Q39910350-73D3A739-82EA-4DBD-BE24-512F4D8321E6

P304

Q39910350-CD89C609-72B0-4F16-BFD2-DAFF7F40F48F

P31

Q39910350-ED2B6CE5-B602-4EB0-B93E-7A550B502A3F

P356

Q39910350-2FCC790D-A6BE-471C-9B98-12FD613A7EE8

P407

Q39910350-05195679-6E45-4A43-B8A7-19171A67C6DA

P433

Q39910350-3C3A130D-518F-4DA5-A01A-98806B756136

P478

Q39910350-CE338E8B-C7D6-4CD1-91EE-6C004F795E5B

P577

Q39910350-C5ED711C-71DB-45B0-B99B-8652B2134439

P698

Q39910350-32F7BDE8-280F-44F7-9554-8741B2F23009

P921

Q39910350-2098869F-8C4B-40A4-9ED2-80C80EDE3B31

P356

0008-5472.CAN-08-1973

P1433

Cancer Research

P1476

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

@en

P2093

Hiroyuki Aburatani

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Tsunoda

http://www.w3.org/2001/XMLSchema#string

Hisafumi Yamada-Okabe

http://www.w3.org/2001/XMLSchema#string

Iwao Ohizumi

http://www.w3.org/2001/XMLSchema#string

Izumi Sugo

http://www.w3.org/2001/XMLSchema#string

Kiyotaka Nakano

http://www.w3.org/2001/XMLSchema#string

Masamichi Sugimoto

http://www.w3.org/2001/XMLSchema#string

Masayuki Tsuchiya

http://www.w3.org/2001/XMLSchema#string

Takahiro Ishiguro

http://www.w3.org/2001/XMLSchema#string

Takao Hamakubo

http://www.w3.org/2001/XMLSchema#string

P304

9832-9838

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-08-1973

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19047163

http://www.w3.org/2001/XMLSchema#string

P921